FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3203062142> ?p ?o ?g. }

• W3203062142 startingPage "150" @default.
• W3203062142 abstract "Background: Paclitaxel has been used widely for various solid tumors such as ovarian, lung and breast cancers. Patients treated with paclitaxel often experience mild to moderate hypersensitivity reactions (HSR) which usually occur at the first or second dose of paclitaxel. Giving premedication regimens consisting of corticosteroid, H1 and H2 antagonists can reduce the incidence of HSR from paclitaxel, but even when premedication is used, HSR can still occur. Objective: To find the incidence of hypersensitivity reactions (HSR) from paclitaxel, including characteristics and severity of paclitaxel-associated hypersensitivity reaction and the effects of premedication regimens used in preventing HSR. Material and Method: Data of patients who received paclitaxel between January 2014 and December 2015 at Rajavithi Hospital were collected from hospital computer databases, pharmacy databases and chemotherapy unit. Patients who received antidotes for paclitaxel HSR were confirmed as having paclitaxel-induced HSR by medical record review. Reports of HSR from adverse drug reactions and risk management units were also included. The severity of HSR was determined in accordance with NCI CTCAE v4.03. All grade 1 or 2 types were classified as mild-moderate HSR, while severe HSR was defined as grade >3. Results: A total of 1,132 patients received paclitaxel 5,152 times, and 48 patients (4.24%) 70 times were found to have HSR resulting from the use of paclitaxel. The severity was mostly grade 2 (55 times). Only one patient had grade 4 and did not continue paclitaxel. The first episode of HSR occurred most frequently at the first (17 patients) and second (26 patients) cycle. Premedication used in this study was divided into 2 groups: Group 1, premedication (oral dexamethasone) was given 6 to 24 hours before paclitaxel; and Group 2, premedication (iv dexamethasone) was given 30 minutes before paclitaxel. In the HSR group, HSR occurred 29.17% (14 from 48 patients, 20 times) in group 1 and 70.83% (34 from 48 patients, 50 times) in group 2. Agricultural patients had a higher incidence of HSR (OR 2.55, 95% CI: 1.20 to 5.43). Lung (14 from 187) and cervical (9 from 141) cancer patients had a higher risk of HSR than other cancer sufferers. Conclusion: The incidence of HSR found in the present research was similar to the results of previous studies in relation to severe HSR. Agricultural workers had a higher risk of HSR, while a premedication regimen of oral dexamethasone 6 to 24 hour before paclitaxel resulted in a lower incidence of HSR. However, the HSR found in both groups was not severe and most patients were able to continue taking paclitaxel. Keywords: Hypersensitivity reactions, Paclitaxel, Premedication" @default.
• W3203062142 created "2021-10-11" @default.
• W3203062142 creator A5038850122 @default.
• W3203062142 creator A5047400579 @default.
• W3203062142 date "2018-02-01" @default.
• W3203062142 modified "2023-09-25" @default.
• W3203062142 title "Incidence of Hypersensitivity Reactions from Paclitaxel" @default.
• W3203062142 cites W1933132098 @default.
• W3203062142 cites W1963704593 @default.
• W3203062142 cites W1966913040 @default.
• W3203062142 cites W1997917050 @default.
• W3203062142 cites W2041155215 @default.
• W3203062142 cites W2041547582 @default.
• W3203062142 cites W2048887152 @default.
• W3203062142 cites W2050707192 @default.
• W3203062142 cites W2080522735 @default.
• W3203062142 cites W2093330266 @default.
• W3203062142 cites W2102982141 @default.
• W3203062142 cites W2151398050 @default.
• W3203062142 cites W2338864821 @default.
• W3203062142 cites W2341826581 @default.
• W3203062142 cites W2613203359 @default.
• W3203062142 hasPublicationYear "2018" @default.
• W3203062142 type Work @default.
• W3203062142 sameAs 3203062142 @default.
• W3203062142 citedByCount "0" @default.
• W3203062142 crossrefType "journal-article" @default.
• W3203062142 hasAuthorship W3203062142A5038850122 @default.
• W3203062142 hasAuthorship W3203062142A5047400579 @default.
• W3203062142 hasConcept C120665830 @default.
• W3203062142 hasConcept C121332964 @default.
• W3203062142 hasConcept C126322002 @default.
• W3203062142 hasConcept C195910791 @default.
• W3203062142 hasConcept C2776694085 @default.
• W3203062142 hasConcept C2777292972 @default.
• W3203062142 hasConcept C2778300832 @default.
• W3203062142 hasConcept C42219234 @default.
• W3203062142 hasConcept C61511704 @default.
• W3203062142 hasConcept C71924100 @default.
• W3203062142 hasConceptScore W3203062142C120665830 @default.
• W3203062142 hasConceptScore W3203062142C121332964 @default.
• W3203062142 hasConceptScore W3203062142C126322002 @default.
• W3203062142 hasConceptScore W3203062142C195910791 @default.
• W3203062142 hasConceptScore W3203062142C2776694085 @default.
• W3203062142 hasConceptScore W3203062142C2777292972 @default.
• W3203062142 hasConceptScore W3203062142C2778300832 @default.
• W3203062142 hasConceptScore W3203062142C42219234 @default.
• W3203062142 hasConceptScore W3203062142C61511704 @default.
• W3203062142 hasConceptScore W3203062142C71924100 @default.
• W3203062142 hasIssue "2" @default.
• W3203062142 hasLocation W32030621421 @default.
• W3203062142 hasOpenAccess W3203062142 @default.
• W3203062142 hasPrimaryLocation W32030621421 @default.
• W3203062142 hasVolume "101" @default.
• W3203062142 isParatext "false" @default.
• W3203062142 isRetracted "false" @default.
• W3203062142 magId "3203062142" @default.
• W3203062142 workType "article" @default.